Relapsed/Refractory HER2+ Metastatic Breast Cancer
This article reviews the recent development of HER2-targeted therapies with central nervous system (CNS) activity that may improve survival of patients with CNS metastases and prevent development of new CNS metastases. This article also features insights from oncology experts Adam M. Brufsky, MD, PhD; V. K. Gadi, MD, PhD; Sara A. Hurvitz, MD; and Neil M. Iyengar, MD.
Advertisement
Advertisement
Trending on CancerNetwork
1
58 An Evidence-Based Self-Management Planner for Patients With Metastatic Triple-Negative Breast Cancer: A Multi-Channel Dissemination Initiative
2
From Conference to Practice: Top 5 Takeaways From EHA 2026
3
57 Altered Biomechanics Drives Outcome in Breast Cancer: A New Avenue for Oncology Biomarkers
4
ASCO 2026: Key Insights In Renal Cell Carcinoma, Merkel Cell Carcinoma, and Chronic Myeloid Leukemia
5